Abeona Therapeutics Says CMS Granted New Technology Add-On Payment Status For ZEVASKYN Under Fiscal Year 2027 Hospital Inpatient Prospective Payment System Final Rule

Abeona Therapeutics, Inc.

Abeona Therapeutics, Inc.

ABEO

0.00

The Centers for Medicare & Medicaid Services (CMS) has granted New Technology Add-On Payment (NTAP) status for ZEVASKYN (prademagene zamikeracel) under the Fiscal Year 2027 Hospital Inpatient Prospective Payment System (IPPS) Final Rule.

NTAP status provides supplemental CMS reimbursement above standard hospital payments to support access to innovative therapies like ZEVASKYN. This additional funding is awarded to technologies that meet CMS criteria, including demonstrating substantial clinical improvement over existing alternatives.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.